3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Sarcoma
1
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
40
Gastro-enteropancreatic neuroendocrine tumor
8
Paraganglioma
5
Pheochromocytoma
4
Neoplasms
2
Carcinoma, Neuroendocrine
2
Carcinoid Tumor
2
Stomach Neoplasms
1
Somatostatin Receptor-positive Neuroendocrine Tumor
1
Sarcoma, Synovial
1
Recurrence
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Osteosarcoma
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Neoplasms, Nerve Tissue
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Meningioma
1
Medulloblastoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hypertension
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Interventions
gallium Ga 68 dotatate
4
fluorodopa F 18
2
Magnetic Resonance Spectroscopy
2
pertuzumab
1
pentetreotide
1
olaparib
1
lutetium Lu 177 dotatate
1
arginyllysine
1
Whole Body Imaging
1
Tretinoin
1
Nivolumab
1
Isotretinoin
1
Furosemide
1
Erlotinib Hydrochloride
1
Amino Acids
1
90Y-octreotide, DOTA-Tyr(3)-
1
4-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
1
3-fluorobenzylguanidine
1
(18F)GTP1
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroblastoma
×
lutetium Lu 177 dotatate
×
NET
×
Clear all
NCT06607692
2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled